Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners.Â
This website uses cookies to collect information in connection with your use of this website. By continuing to use this website, you agree to the use of all our cookies, which includes new versus returning visitors and country location only. We do not collect personal information. Privacy Notice & Terms and Conditions